Endotoxemia in Acute Heart Failure and Cardiogenic Shock: Evidence, Mechanisms and Therapeutic Options.
Fiche publication
Date publication
mars 2023
Journal
Journal of clinical medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MASSON David
Tous les auteurs :
Nguyen M, Gautier T, Masson D, Bouhemad B, Guinot PG
Lien Pubmed
Résumé
Acute heart failure and cardiogenic shock are frequently occurring and deadly conditions. In patients with those conditions, endotoxemia related to gut injury and gut barrier dysfunction is usually described as a driver of organ dysfunction. Because endotoxemia might reciprocally alter cardiac function, this phenomenon has been suggested as a potent vicious cycle that worsens organ perfusion and leading to adverse outcomes. Yet, evidence beyond this phenomenon might be overlooked, and mechanisms are not fully understood. Subsequently, even though therapeutics available to reduce endotoxin load, there are no indications to treat endotoxemia during acute heart failure and cardiogenic shock. In this review, we first explore the evidence regarding endotoxemia in acute heart failure and cardiogenic shock. Then, we describe the main treatments for endotoxemia in the acute setting, and we present the challenges that remain before personalized treatments against endotoxemia can be used in patients with acute heart failure and cardiogenic shock.
Mots clés
acute heart failure, cardiogenic shock, endotoxemia, lipopolysaccharide, translocation
Référence
J Clin Med. 2023 03 29;12(7):